Biotechnology - Ophthalmics

Filter

Current filters:

Ophthalmics

Popular Filters

1 to 25 of 32 results

Rigel’s R348 fails to meet endpoints in Ph II dry eye study

13-08-2014

Clinical-stage US drug developer Rigel Pharmaceuticals says that R348, its ophthalmic JAK/SYK inhibitor,…

BiotechnologyDry eye diseasefostamatinibOphthalmicsR118R348ResearchRigel Pharmaceuticals

Genentech files sBLA for Lucentis for diabetic retinopathy

09-08-2014

Genentech, the biotech subsidiary of Swiss pharma major Roche, has submitted a supplemental Biologics…

BiotechnologyGenentechLucentisOphthalmicsRegulationRocheUSA

Eylea drives Regeneron’s 2nd-qtr to beat expectations

Eylea drives Regeneron’s 2nd-qtr to beat expectations

05-08-2014

USA-based biotech company Regeneron (Nasdaq: REGN) revealed today that total revenues for the second…

BiotechnologyBusiness FinanceEyleaFinancialOphthalmicsRegeneronUSA

Regeneron’s Eylea gains FDA approval for DME

Regeneron’s Eylea gains FDA approval for DME

30-07-2014

The Food and Drug Administration has approved US biotech firm Regeneron Pharmaceuticals’ Eylea (aflibercept)…

BayerBiotechnologyEyleaOphthalmicsRegeneronRegulationUSA

Sustained improvement in vision among two-year results from Phase III Eylea trial

Sustained improvement in vision among two-year results from Phase III Eylea trial

18-07-2014

US-based biotech company Regeneron has said its Phase III trials of Eylea (aflibercept) injection for…

afliberceptBayerBiotechnologyDiabetic retinopathyEyleaLaser coagulationMacular edemaOphthalmicsRegeneronResearchUSA

NicOx to acquire Aciex Therapeutics

02-07-2014

Ophthalmology-focused French biotech firm NicOx has entered into an agreement to acquire all of the outstanding…

Aciex TherapeuticsBiotechnologyInflammatory diseasesMergers & AcquisitionsNicOxOphthalmics

NicOx launches commercial operations in Germany

30-06-2014

Ophthalmology-focused French biotech firm NicOx has today announced the launch of its German operations.

AdenoPlusBiotechnologyGermanyManagementMarkets & MarketingNicOxOphthalmicsXailin

ThromboGenics plans to remain independent

24-06-2014

In response to market rumors, Belgian biotech firm ThromboGenics today issues an update on the Strategic…

BiotechnologyJetreaManagementOphthalmicsThromboGenics

Israel’s OphthaliX updates on clinical developments and strategic plans

09-06-2014

Israel-based OphthaliX, a majority-owned subsidiary of biotech firm Can-Fite BioPharma focussed on ophthalmic…

BiotechnologyCan-Fite BioPharmaLicensingOphthaliXOphthalmicsResearch

Novartis in up to $1 billion deal to acquire ex-US rights to Fovista

Novartis in up to $1 billion deal to acquire ex-US rights to Fovista

20-05-2014

Swiss pharma major Novartis has signed a licensing and commercialization agreement with US biotech firm…

BiotechnologyFovistaLicensingNovartisOphthalmicsOphthotech

First Asian approval for ophthalmic drug Jetrea, in Malaysia

18-04-2014

Belgian biotech firm ThromboGenics NV revealed today that Jetrea (ocriplasmin) has been approved in Malaysia…

AlconAsia-PacificBiotechnologyJetreaMalaysiaNovartisOphthalmicsRegulationThromboGenics

ThromboGenics announces 2013 growth thanks to Jetrea sales

ThromboGenics announces 2013 growth thanks to Jetrea sales

18-03-2014

Belgium-based biopharma firm ThromboGenics has released its financial results for the full year 2013,…

BelgiumBiotechnologyFinancialJetreaOphthalmicsThromboGenics

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Oxford BioMedica concludes novel ocular license deal with Sanofi

Oxford BioMedica concludes novel ocular license deal with Sanofi

17-02-2014

UK-based Oxford BioMedica has concluded the terms of the development and commercialization license agreement…

BiotechnologyLicensingOphthalmicsOxford BioMedicaUK

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

PDL BioPharma settles litigation with Genentech and Roche

03-02-2014

US drugmaker PDL BioPharma has entered into an agreement with Genentech and its parent, Swiss drug major…

BiotechnologyFinancialGenentechLegalOncologyOphthalmicsPDL BioPharmaRoche

Nicox granted exclusive promotion and marketing rights for AMD test in North America

17-01-2014

French biotech firm NicOx SA (NYSE Euronext Paris: COX) and USA-based Sequenom (Nasdaq: SQNM) have entered…

BiotechnologyFranceLicensingNicOxOphthalmicsSequenomUSA

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

17-01-2014

Belgian biotech firm ThromboGenics says that the Transparency Commission of the French National Health…

AlconBiotechnologyJetreaNovartisOphthalmicsPricingThromboGenics

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

NicOx highlights progress in bid to focus on ophthalmology

07-01-2014

French biotech firm NicOx SA (NYSE Euronext Paris: COX) says it has made significant progress in 2013…

BiotechnologyFinancialFranceNicOxOphthalmics

1 to 25 of 32 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top